ArticleCureus2025
Fludrocortisone for Refractory Hypotension in a Hospitalized Dialysis Patient: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We present the case of a 74-year-old woman with stage 4 chronic kidney disease (CKD) who developed acute kidney injury (AKI) due to drug-induced acute interstitial nephritis (AIN) following exposure to piperacillin-tazobactam 2.25 grams three times a day and ursodiol 600 mg daily. Despite corticosteroid therapy, her renal function declined, necessitating the initiation of maintenance hemodialysis. During a subsequent admission, she developed persistent intradialytic hypotension (IDH), with her systolic blood pressure ranging from 60 to 70 mm Hg and diastolic blood pressure ranging from 35 to 45 mm Hg. Laboratory evaluation revealed a low morning cortisol level, consistent with adrenal insufficiency secondary to prior steroid use. ACTH stimulation testing was not performed due to the patient's clinical instability; however, recent corticosteroid use, persistent hypotension, low cortisol levels, and volume overload provided sufficient evidence of secondary adrenal insufficiency to guide management. The patient was commenced on stress-dose hydrocortisone and midodrine, but hypotension persisted. The addition of fludrocortisone resulted in sustained hemodynamic improvement by enhancing sodium and water retention, as well as improving vascular tone. Her blood pressure improved, with systolic values ranging from 98 to 105 mm Hg and diastolic values from 55 to 65 mm Hg. This enabled successful hemodialysis tolerance over the following 2.5 months. Informed consent for publication of this case and its accompanying details was obtained from the patient's family. Fludrocortisone, commonly used in ambulatory dialysis, proved valuable in this case by demonstrating efficacy in the acute inpatient setting, initiated at a dose of 0.1 mg and titrated to 0.2 mg daily. It underscores the therapeutic role of fludrocortisone in managing refractory hypotension due to adrenal insufficiency, even in patients with minimal residual renal function, and emphasizes the importance of early recognition and treatment of corticosteroid-induced adrenal suppression in CKD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.